These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 22321702)

  • 21. Identification and molecular characterization of triple- and quadruple-resistant Helicobacter pylori clinical isolates in Germany.
    Wueppenhorst N; Stueger HP; Kist M; Glocker E
    J Antimicrob Chemother; 2009 Apr; 63(4):648-53. PubMed ID: 19190100
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen.
    Rokkas T; Sechopoulos P; Robotis I; Margantinis G; Pistiolas D
    Am J Gastroenterol; 2009 Jan; 104(1):21-5. PubMed ID: 19098844
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of metronidazole for the treatment of clarithromycin-resistant Helicobacter pylori infection in a Japanese population.
    Shimoyama T; Fukuda S; Mikami T; Fukushi M; Munakata A
    J Gastroenterol; 2004 Oct; 39(10):927-30. PubMed ID: 15549444
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High Helicobacter pylori cure rate with sitafloxacin-based triple therapy.
    Sugimoto M; Sahara S; Ichikawa H; Kagami T; Uotani T; Furuta T
    Aliment Pharmacol Ther; 2015 Aug; 42(4):477-83. PubMed ID: 26075959
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.
    Köksal AS; Parlak E; Filik L; Yolcu OF; Odemiş B; Ulker A; Saşmaz N; Ozden A; Sahin B
    J Gastroenterol Hepatol; 2005 Apr; 20(4):637-42. PubMed ID: 15836716
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduced symptoms and need for antisecretory therapy in veterans 3 years after Helicobacter pylori eradication with ranitidine bismuth citrate/amoxicillin/clarithromycin.
    Sontag SJ; O'Connell S; Schnell T; Chejfec G; Seidel J; Sonnenberg A
    Am J Gastroenterol; 2001 May; 96(5):1390-5. PubMed ID: 11374672
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Failure of first-line eradication treatment significantly increases prevalence of antimicrobial-resistant Helicobacter pylori clinical isolates.
    Romano M; Iovene MR; Russo MI; Rocco A; Salerno R; Cozzolino D; Pilloni AP; Tufano MA; Vaira D; Nardone G
    J Clin Pathol; 2008 Oct; 61(10):1112-5. PubMed ID: 18755715
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first- and second-line therapies.
    Matsuzaki J; Suzuki H; Nishizawa T; Hirata K; Tsugawa H; Saito Y; Okada S; Fukuhara S; Hibi T
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1643-5. PubMed ID: 22203601
    [TBL] [Abstract][Full Text] [Related]  

  • 29. GenoType HelicoDR test in the determination of antimicrobial resistance of Helicobacter pylori in Korea.
    Lee JW; Kim N; Nam RH; Park JH; Choi YJ; Kim JM; Kim JS; Jung HC
    Scand J Gastroenterol; 2014 Sep; 49(9):1058-67. PubMed ID: 24957849
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of faropenem in eradication therapy of Helicobacter pylori.
    Ogura K; Mitsuno Y; Maeda S; Hirata Y; Yanai A; Shibata W; Ohmae T; Yoshida H; Kawabe T; Omata M
    Helicobacter; 2007 Dec; 12(6):618-22. PubMed ID: 18001403
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Duration of the metronidazole-containing regimen for eradication of Helicobacter pylori infection in northern Japan.
    Fukuda S; Shimoyama T; Tanaka M; Nakasato F; Fukushi M; Munakata A
    Jpn J Infect Dis; 2006 Dec; 59(6):367-9. PubMed ID: 17186954
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship between eradication therapy and clarithromycin-resistant Helicobacter pylori in Japan.
    Hoshiya S; Watanabe K; Tokunaga K; Tanaka A; Ninomiya H; Shingaki M; Itoh T; Saito S; Ishida H; Takahashi S
    J Gastroenterol; 2000; 35(1):10-4. PubMed ID: 10632534
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens.
    Schwartz H; Krause R; Sahba B; Haber M; Weissfeld A; Rose P; Siepman N; Freston J
    Am J Gastroenterol; 1998 Apr; 93(4):584-90. PubMed ID: 9576452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Present status and future prospect of 3rd rescue regimen for H. pylori infection].
    Furuta T
    Nihon Rinsho; 2009 Dec; 67(12):2303-8. PubMed ID: 19999116
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The importance of the level of metronidazole resistance for the success of Helicobacter pylori eradication.
    Wheeldon TU; Granström M; Hoang TT; Phuncarg DC; Nilsson LE; Sörberg M
    Aliment Pharmacol Ther; 2004 Jun; 19(12):1315-21. PubMed ID: 15191514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resistance rate to antibiotics of Helicobacter pylori isolates in eastern Taiwan.
    Hu CT; Wu CC; Lin CY; Cheng CC; Su SC; Tseng YH; Lin NT
    J Gastroenterol Hepatol; 2007 May; 22(5):720-3. PubMed ID: 17444862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Influence of resistance of Helicobacter pylori to antibiotics on the Helicobacter pylori eradication regimens].
    Cheng H; Hu FL; Li J
    Zhonghua Yi Xue Za Zhi; 2006 Oct; 86(38):2679-82. PubMed ID: 17199976
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effectiveness of triple therapy to eradicate H. pylori in patients after failed therapy with omeprazole/amoxicillin].
    Zala G; Schwery S; Giezendanner S; Flury R; Wüst J; Meyenberger C; Wirth HP
    Schweiz Med Wochenschr; 1996 Feb; 126(5):153-8. PubMed ID: 8685685
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection.
    Wong WM; Gu Q; Chu KM; Yee YK; Fung FM; Tong TS; Chan AO; Lai KC; Chan CK; Wong BC
    Aliment Pharmacol Ther; 2006 Feb; 23(3):421-7. PubMed ID: 16423001
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The efficacy of two-week therapy with ranitidine bismuth citrate, amoxicillin and clarithromycin on Helicobacter pylori eradication in clarithromycinresistant and- sensitive cases.
    Aydin A; Onder GF; Akarca US; Tekin F; Tunçyürek M; Musoğlu A
    Turk J Gastroenterol; 2005 Dec; 16(4):203-6. PubMed ID: 16547848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.